Kiniksa Pharmaceuticals International, plc: stock overview

KNSANASDAQHealthcare · Pharmaceutical Preparations

Price

$96.33

November 13, 2026Market cap $7.1B

DCF calculator

What Ploutos Investor adds for Kiniksa Pharmaceuticals International

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 5 fiscal years, from 2021
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Kiniksa Pharmaceuticals International had revenue of $946M over the last 12 months and net income of $110M, a net margin of 11.6%. Revenue grew by 104.8% a year on average over the last 4 years. At $96.33 the shares trade at a P/E of 65.2, against a median of 55.0 over the last 3 fiscal years. It holds more cash than debt, by $569M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$7.1B
74.20M shares
P/E
65.2
Today65.2
Median55.0
Revenue, 12 months
$946M
+104.8% a year over 4 years
Net margin
11.6%
2025: 8.7%, above 73% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+58.3% a year over 2 years

  • 202510-K
    Revenue$678M
  • 202410-K
    Revenue$423M
  • 202310-K
    Revenue$270M

Fiscal years in figures

KNSA's revenue, profit, cash flow and dividend with each year-end price, from 2021 to 2022, 2 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $1.4B
$7.1B
Enterprise value 
$6.6B
P/E 
65.2
EV / EBIT 
50.4
EV / Revenue 
7.0
P/B 3-year median: 3.2
10.1
FCF yield 3-year median: 1.8%
2.8%
Earnings yield 3-year median: 1.1%
1.5%

Profitability

Gross margin 
90.2%
Operating margin 
13.8%
Net margin 3-year median: 5.2%
11.6%
ROIC 
15.9%
ROIC, 5-year average 
-13.4%
ROE 
17.8%

Growth

Revenue, yearly change 
+60.1%
EPS, yearly change 
–
FCF, yearly change 
+436.8%
Revenue, average a year 
+104.8%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$569M
Total debt 
$7.9M
Of which operating leases 
$7.9M
Net cash 
$569M
Net debt / EBITDA 
-4.3x
Interest cover 
–
Current ratio 
3.91

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+3.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

11.4%

Above 73% of the 285 companies in its industry, and 67% of all.

Net margin

8.7%

Above 73% of the 302 companies in its industry, and 63% of all.

ROE

10.4%

Above 68% of the 267 companies in its industry, and 62% of all.

ROA

7.7%

Above 77% of the 313 companies in its industry, and 82% of all.

Revenue growth

60.1%

Above 88% of the 292 companies in its industry, and 96% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Kiniksa Pharmaceuticals International, plc
CIK
1730430
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
74.20M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Kiniksa Pharmaceuticals International's filings show?

These are Kiniksa Pharmaceuticals International's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about KNSA

Didn't find what you were looking for?

Ask us
What is KNSA's market cap?

Kiniksa Pharmaceuticals International, plc's market cap is $7.1B, at a price of $96.33 on November 13, 2026 and 74.20M shares.

What is KNSA's P/E?

KNSA's P/E is 65.2, on earnings per share of $1.31 over the last 12 months. The median over the last 3 fiscal years was 55.0.

How much revenue does KNSA have?

Kiniksa Pharmaceuticals International had revenue of $946M over the last 12 months. Over the last 4 years it changed by +104.8% a year on average.

Does KNSA pay a dividend?

No. Kiniksa Pharmaceuticals International paid no regular dividend over the last 12 months.

Where do the figures come from?

From Kiniksa Pharmaceuticals International, plc's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.